Lineage Cell Therapeutics
LCTX
97 hedge funds and large institutions have $52.9M invested in Lineage Cell Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 27 reducing their positions, and 16 closing their positions.
0.32% more ownership
Funds ownership: 42.29% → 42.62% (+0.32%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less capital invested
Capital invested by funds: $56.4M → $52.9M (-$3.52M)
10% less funds holding
Funds holding: 108 → 97 (-11)
33% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 27
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$438K |
| 2 |
Renaissance Technologies
New York
|
+$267K |
| 3 |
Jane Street
New York
|
+$141K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$124K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$190K |
| 2 |
Morgan Stanley
New York
|
-$138K |
| 3 |
Bank of New York Mellon
New York
|
-$84.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$84.6K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$83.9K |
LCTX Hedge Fund Activity: Q1 2020 in Review
97 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2020, worth a combined $52.9M — down 6.2% from $56.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LCTX and 7 opened new positions — a net loss of 9 holders — while 27 trimmed existing stakes and 18 added.
The largest buyer was Defender Capital, adding an estimated $438K. The largest seller was Two Sigma Investments, cutting an estimated $190K.
- 97 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2020, down from 108 in Q4 2019.
- Funds reported $52.9M of Lineage Cell Therapeutics stock for Q1 2020, down 6.2% quarter-over-quarter.
- 7 funds opened new Lineage Cell Therapeutics positions in Q1 2020 and 16 closed out, a net change of -9 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2020 was Defender Capital, an estimated $438K added.
- The largest Lineage Cell Therapeutics seller in Q1 2020 was Two Sigma Investments, an estimated $190K sold.
Based on aggregated 13F filings for Q1 2020.